Why ophthalmic regulation is not one global pathway
Novel ophthalmic therapies — particularly intravitreal biologics, depot formulations, and drug-device combinations — often receive different questions from FDA and EMA reviewers even when sponsors pursue harmonized protocols. Endpoint acceptability, durability of effect, and injection-related safety can be interpreted differently across regions.
Pre-IND and Scientific Advice as leverage points
Formal agency meetings remain among the highest-return activities for ophthalmic programs. Structured briefing packages that present a primary position, supporting precedents, and fallback options reduce ambiguity after interactions. Mock Q&A with clinical, CMC, and regulatory leads present prevents inconsistent responses that delay written feedback.
Endpoints: structural, functional, and patient-reported measures
Regulators expect clear hierarchies linking mechanism to OCT or angiography findings and to functional vision outcomes. Sponsors should document why chosen endpoints are sensitive to treatment effect in the target population and how missing data and inter-eye correlation are handled statistically — especially in bilateral disease.
Combination products and sustained delivery
When delivery technology affects pharmacokinetics or administration setting, agencies evaluate CMC, device, and clinical narratives together. Gap analyses should reference ophthalmic combination-product precedents and clarify which studies bridge formulation or device changes without repeating full efficacy trials.
Regional sequencing after core approvals
US approval does not automatically translate to rapid EU or Asia-Pacific access. HTA evidence requirements, pricing negotiations, and local comparator landscapes should inform country sequencing. Sponsors benefit from a single global evidence plan with defined regional adaptations rather than reactive submissions.
